Adaptive Biotechnologies (ADPT) reported $71.55 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 21.5%. EPS of -$0.10 for the same period compares to -$0.17 a year ago.The reported revenue represents a surprise of +7.98% over the Zacks Consensus Estimate of $66.27 million. With the consensus EPS estimate being -$0.13, the EPS surprise was +23.08%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectati ...